GWPH News and Press, GW Pharmaceuticals Plc From 04/13/21

EPIDOLEX encore presentations highlight long-term safety and efficacy data in patients with tuberous sclerosis complex (TSC) and other treatment-resistant epilepsies Nabiximols data show efficacy and safety results in patients with spasticity associated with multiple sclerosis ...

Downward Pressure For Top Marijuana Stocks Marijuana stocks have started this week in April showing some downside in the market. One factor that probably played a part in the downturn in the cannabis sector is a disappointing third-quarter fiscal 2021 report from Aphria Inc. ( NASDAQ:...

When GW Pharmaceuticals ' (NASDAQ: GWPH) cannabidiol-based drug, Epidiolex, came onto the pharmaceutical scene, cannabis investors rejoiced. Jazz Pharmaceuticals (NASDAQ: JAZZ) recently announced plans to acquire GW Pharma, and to bring its seizure treatment into a larger po...

Merck & Co. is a large legacy company that makes a profit, pays a consistent dividend, and is a familiar and dependable company. That sometimes makes for boring. Analysts have a consensus target price in the mid-$90s while it might be undervalued by over 50%. Merck develops an...

The Cannabis Sector And April Volatility One question many investors are asking themselves in April is how will marijuana stocks perform this month? After a significant drop in March, most leading cannabis stocks began regaining value at the top of April. But on April 7th the cannab...

Flying High: The emerging Cannabis REIT sector has been far-and-away the best-performing property sector since the start of 2019, soaring more than 150% in 2020 following 70% gains the prior year. The momentum has continued this year after New York became the 15th state to fully legal...

Why aren't US cannabis stocks reflecting more fundamental bullish developments? CNBC's Tim Seymour joins us to discuss this and his actively managed ETF, CNBS. Top line revenue will be very robust this year. SAFE Banking and waiting to hear what happens in Texas. Cannabis coverage...

Cannabis research -- even for medical purposes -- is highly restricted in the United States. But we have seen plenty of glimmers of hope about its benefits, and signals that cannabis can treat severe disease. Take, for instance, Jazz Pharmaceuticals' (NASDAQ: JAZZ) recent announceme...

Merger activity increased last week. The bidding war for Coherent comes to an end. The acquisition of MSG Networks (MSGN) by Madison Square Garden Entertainment. For further details see: Merger Arbitrage Mondays - Multiple Deals In Bidding Wars

There has been a surge of mergers and acquisitions activity in the cannabis industry of late. Aphria (NASDAQ: APHA) and Tilray (NASDAQ: TLRY) are linking up in one of the sector's highest-profile mergers, and other industries are getting in on the action. Jazz Pharmaceutic...